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Abstract
Background—Hepatitis C virus (HCV) infection is unidentified in an estimated 40%–85% of 
infected adults. Surveillance and modeling data have found significant increases in HCV-
associated morbidity and mortality.
Purpose—To compare two HCV antibody (anti-HCV) testing strategies based on (1) elevated 
alanine aminotransferase levels (ALT) and (2) a birth cohort approach for people born during 
1945–1965.
Methods—Data from 19,055 adults aged 20–70 years who completed the National Health and 
Nutrition Examination Survey in 1999–2008 were analyzed in 2013. Two independent models 
were evaluated, based on membership in the 1945–1965 birth cohort or elevated ALT, to compare 
the number of identified anti-HCV-positive (anti-HCV+) individuals; proportion of total identified 
cases; and the number of people that would be tested using either strategy.
Results—The prevalence of anti-HCV among adults aged 20–70 years was estimated at 2.0% 
(95% CI=1.8%, 2.3%), representing about 3.6 million people. The birth cohort strategy would 
result in testing about 85.4 million people and identifying nearly 2.8 million anti-HCV+ people 
with a sensitivity of 76.6%. The ALT strategy would test about 21.5 million adults and identify 
approximately 1.8 million anti-HCV+ people with a sensitivity of 50.0%. Implementing both 
strategies concurrently would identify 87.3% of anti-HCV+ adults.
Conclusions—The birth cohort strategy, which is recommended by both the CDC and the U.S. 
Preventive Services Task Force, would identify 1 million more anti-HCV+ people than the 
elevated ALT approach. Concurrent implementation would identify an even larger number of 
individuals ever infected.
Introduction
An estimated 4 million people have previously been infected with hepatitis C virus (HCV) in 
the U.S.1 All individuals infected with HCV develop antibodies (anti-HCV) and about 75%–
85% have evidence of HCV-RNA, indicating chronic (current) infection.1,2 Most people 
living with HCV infection are adults in their late forties to late sixties and thought to have 
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been infected 25–45 years ago.3,4 Without testing and treatment over their lifetimes, the 
CDC estimates that 60% of people with HCV infection will develop cirrhosis.5
In 2007, HCV infection surpassed HIV as an underlying or contributing cause of mortality 
and accounted for more than 15,000 deaths in the U.S.6 It is projected that among adults 
with untreated HCV infection, 37% (1,071,000) will die from complications of hepatitis C in 
their lifetimes.5 Recent advances in direct-acting antiviral medications for HCV infection 
have increased cure rates to 90% in clinical trials.7,8 However, any benefit from these new 
treatments requires identification of people with current infection.
Previous studies have estimated that 40%–85% of infected individuals may be undiagnosed 
and are not aware of their infection, methods to reduce the progression of their liver disease, 
or behavioral steps to avoid transmission.9–14 Although risk-based testing can in principle 
identify approximately 79%–99% of HCV-infected people,1,15,16 it has been limited in its 
effectiveness in routine clinical practice.15,17–21 For example, only 58%–63% of primary 
care providers inquire about patients’ history of risk factors for HCV infection.19–21 When 
probed, patients may not fully disclose past or current exposures.22–26
Additionally, an estimated 20%–30% of HCV-infected individuals do not report any risk 
factors and would not be identified by risk-based screening strategies.13,14,27 It has been 
suggested that provider motivation and the amount of clinical staff resources (e.g., time) 
required for adequate and sustainable evaluation of patients for risk factors may represent 
further limitations to risk-based testing.13,28,29
Alanine aminotransferase (ALT) is an enzyme produced by the liver that is a moderately 
sensitive indicator of liver injury when elevated; therefore, the CDC and the American 
Association for the Study of Liver Disease both recommend HCV testing for persons with 
elevated ALT levels.30,31 Studies suggest that providers are more likely to test patients for 
HCV based on elevated ALT than on assessment of exposure risk factors.17,32
The prevalence of HCV infection among individuals with elevated ALT levels may be 
several-fold higher compared with those with normal ALT levels.1,10,11,33 Thus, it has been 
suggested that HCV testing based on abnormal ALT levels alone could be used to identify 
56%–69% of asymptomatic anti-HCV-positive (anti-HCV+) people.30,34 However, three 
recent studies9,15,35 in eight unique primary care settings found that of all people with 
elevated ALT, 43%–86% were not tested for anti-HCV.
Testing all individuals with elevated ALT would require that these levels be measured as part 
of routine care and providers have ready access to results; however, current literature35–38 
suggests that only an estimated 46% of patients are evaluated for liver function. The ALT 
strategy also has other limitations, including lack of a standard definition for the upper limit 
of normal (ULN)39,40; sensitivity to demographic subgroups (i.e., gender, race/
ethnicity)41–46; alcohol consumption; fatty liver45; and the requirement for multiple tests 
over time to establish persistence.45,47
In 2012, the CDC recommended a one-time HCV test48 for people born during 1945–1965, 
a high-prevalence cohort that is estimated to account for 67%–76% of adult HCV 
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infections.1,16,49 The purpose of this analysis is to compare the sensitivity, number of 
identified cases, and size of the population that would be tested using either the birth cohort 
or elevated ALT testing strategy.
Methods
Study Population
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, 
nationally representative, multistage, stratified probability cluster survey of the U.S civilian, 
non-institutionalized population. Each participant is interviewed and medically examined, 
during which biological specimens are collected for laboratory testing. Information on 
informed consent procedures, the survey design, and implementation is discussed in the 
survey documentation.50 Data collected from 1999 to 2008 were analyzed. Analysis was 
restricted to participants aged 20–70 years at the time of survey who were interviewed, 
medically examined, and provided samples for anti-HCV testing. Participants without 
specimens for testing and those with indeterminate anti-HCV test results were excluded 
from the final analytic sample.
Outcome Variable
The outcome measure was anti-HCV prevalence as determined by serologic testing. 
Specimens were tested for HCV antibodies by repeated enzyme-linked immunosorbent 
assay (ELISA version 3.0; Ortho Diagnostic Systems, Inc., Raritan NJ). All anti-HCV+ 
specimens were confirmed by recombinant immunoblot assay (RIBA version 3.0; Chiron 
Corporation, Emeryville CA). Participants who tested positive by both ELISA and RIBA 
were considered anti-HCV+. Further, HCV-RNA testing results were not available for all 
cycles of NHANES and were not included in this study.
Anti-HCV Testing Variables
Participants’ birth year and ALT levels were selected as the variables for evaluation of anti-
HCV testing strategies. Birth year was estimated by subtracting participant age at time of 
survey from the estimated year in which the participant was surveyed.51 Persons with birth 
year 1945–1965 were classified as being within the birth cohort. Elevated ALT was defined 
as ≥40 IU/L based on a one-time measurement of serum ALT activity (Hitachi 917, Roche 
Diagnostics, Indianapolis IN [1999–2001]; Beckman Synchron LX20 and DxC800, 
Beckman Coulter, Inc., Fullerton CA [2002–2008]). The analytic sensitivity and range of the 
different analyzers were similar and the distributions of ALT activity did not differ 
significantly.52–58
Other Variables
The following demographic and risk factors were included based on review of the 
literature1,49 and public health significance: race/ethnicity; gender; veteran status; family 
income; health insurance status; daily alcohol consumption within the past 12 months; 
lifetime injection drug use (IDU; cocaine, heroin, and methamphetamine); and history of 
blood transfusion before 1992. NHANES questions related to history of injection drug use 
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are restricted to adult participants aged 20–59 years. All analyses involving IDU were 
similarly restricted.
Statistical Analysis
Weighted means, proportions, SEs, and 95% CIs were estimated to describe participant 
characteristics. Weighted estimates of anti-HCV prevalence were derived for all adults aged 
20–70 years and by subgroups. Differences in prevalence between subgroups were 
determined by specifying linear contrasts. Statistical significance was defined as a two-sided 
p-value < 0.05.
Two models were evaluated using the birth cohort and ALT testing strategies applied to the 
target population of persons aged 20–70 years. For the birth cohort strategy, it was assumed 
that all persons born during 1945–1965 would receive a one-time anti-HCV test. Sensitivity 
was defined as the number of anti-HCV+ people within the birth cohort divided by the total 
number of anti-HCV+ individuals aged 20–70 years.
Similarly, for the ALT strategy, it was assumed that all participants would have ALT test 
results available and those with elevated ALT levels would be tested for anti-HCV. For this 
strategy, sensitivity was calculated as the number of anti-HCV+ people with elevated ALT 
divided by the total number of anti-HCV+ people aged 20–70 years. Sensitivity analyses 
were subsequently performed to examine the impact of (1) using alternate cut-off levels for 
the ALT ULN (i.e., 31 U/L for men and 20 U/L for women, in comparison to the standard 40 
U/L for both genders)45 or (2) testing everyone in the 1945–1965 birth cohort in addition to 
testing adults outside the birth cohort who have elevated (≥40 U/L) ALT levels.
Data were analyzed using SAS-callable SUDAAN, version 10.0.1 (RTI International, 
Research Triangle Park NC) to account for the complex survey design. Sampling and design 
variables published by NHANES were used to account for the probability of being 
medically examined and tested for anti-HCV.50 Sample weights were rescaled after 
combining data across multiple survey years.59 Variance and SEs were estimated using the 
Taylor linearization method. Data analyses were completed in 2013.
Results
Participant Characteristics
The estimated interview response rate for adults aged 20–70 years from 1999 to 2008 was 
76.4% (n=21,313/27,897) (Figure 1). Of the 21,313 participants who were interviewed, 
20,341 (95.4%) were medically examined and 19,130 provided specimens for anti-HCV 
testing. The final analytic sample consisted of 19,055 participants (93.7% of those 
examined) following exclusion of participants with indeterminate anti-HCV results (n=75).
Characteristics of the study population are reported in Table 1. The average age of the 
participants was 42.7 years (SE=0.2 years). Approximately 10.9% (95% CI=9.4%, 12.6%) 
of participants were non-Hispanic black; 46.8% (45.8%, 47.9%) were in the birth cohort; 
2.1% (1.8%, 2.5%) reported past or current injection drug use; 6.3% (5.9%, 6.8%) received 
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blood transfusion before 1992; and 11.8% (11.2%, 12.4%) had elevated ALT levels (Table 
1).
Among anti-HCV+ participants, 43.4% (95% CI=37.6%, 49.5%) reported a history of IDU; 
15.2% (11.3%, 20.1%) received blood transfusion prior to 1992; 57.6% (51.4%, 63.5%) 
reported drinking two or more alcoholic beverages per day; and 34.7% (29.2%, 40.5%) were 
uninsured (Table 1). Cumulatively, people with a documented history of IDU or blood 
transfusion accounted for 53.8% (48.4%, 59.2%) of anti-HCV+ participants.
Prevalence of Anti-HCV
Anti-HCV prevalence estimates are reported in Table 2. The overall prevalence of anti-HCV 
among adults aged 20–70 years was estimated at 2.0% (95% CI=1.8%, 2.3%). Based on 
population estimates from the 1999–2008 Current Population Surveys,60 this corresponds to 
about 3.6 million non-institutionalized civilian adults with HCV antibodies. Anti-HCV 
prevalence was higher among participants born during 1945–1965 (3.2% [2.8%, 3.8%]) 
compared to those outside the birth cohort (0.9% [0.7%, 1.1%]), as well as among 
participants with elevated ALT levels (8.4% [7.0%, 9.9%]) compared to those with normal 
ALT levels (1.1% [0.9%, 1.3%]).
Comparison of Birth Cohort and ALT Testing Strategies
The average population of adults aged 20–70 years represented in the 1999–2008 NHANES 
cycles was nearly 182.8 million.60 Using the birth cohort strategy as the testing criterion, 
about 85.4 million people would be tested for anti-HCV and about 2.8 million individuals 
with anti-HCV would be identified, yielding a sensitivity of 76.6% (Table 3). In contrast, the 
ALT strategy would result in testing 21.5 million adults and identifying 1.8 million anti-
HCV+ people with a sensitivity of 50.0%. In addition, assuming that 75%–85% of anti-HCV
+ persons are currently infected, testing everyone within the birth cohort would identify an 
estimated 2.1–2.4 million current HCV infections compared to 1.4–1.5 million for the ALT 
strategy (Table 3).
In a sensitivity analysis using a ULN of 31 U/L for men and 20 U/L for women,45 it was 
estimated that 72.8 million adults would be tested and 75.7% of anti-HCV+ people 
(men=75.1%, women=76.8%) would be identified. If the birth cohort strategy was 
implemented, and, at the same time, the ALT strategy was implemented among people 
outside the birth cohort, 87.3% of anti-HCV+ adults aged 20–70 years would be identified.
Discussion
Our findings indicate that targeting the high-prevalence birth cohort for HCV testing has the 
potential to identify about 1 million more anti-HCV+ people compared to a strategy based 
on a single elevated ALT result. The prevalence of anti-HCV within the birth cohort is about 
four times that in the adult population born before 1945 or after 1965, and using the birth 
cohort as the basis of anti-HCV testing would identify nearly 77% of anti-HCV cases in the 
U.S. adult population compared to 50% identified using the ALT strategy.
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Most adults currently living with HCV were likely infected 25–45 years ago3,4 and may not 
admit to or recall past behaviors that put them at risk for HCV infection. The high 
prevalence of HCV infection in the 1945–1965 birth cohort is most often the consequence of 
receipt of a blood transfusion prior to 1992 or of IDU1,4; others may have acquired HCV 
infection through health care (e.g., kidney dialysis) or use of blood-clotting products.4,49,61 
Although our analysis confirmed IDU and blood transfusion as important transmission risk 
factors responsible for more than 54% of anti-HCV+ cases, another 46% did not report 
either of these exposure risk factors. The birth cohort testing strategy does not rely on 
solicitation of risk factors and would test all members of the birth cohort even if they do not 
disclose historic exposures to HCV risk factors.
In contrast, the ALT strategy would mean testing 60 million fewer people but would fail to 
identify approximately 700,000–900,000 with current HCV infection (Table 3). By various 
estimates, approximately 30%–50% of individuals with current HCV infection demonstrate 
persistently normal ALT levels (PNALT)62–65 and would not be identified by an ALT test. 
More concerning, one third of HCV-infected people with PNALT have significant fibrosis 
progression and could be treated if diagnosed.65–66 Other limitations of the ALT strategy 
include sensitivity to age, race, gender, and alcohol consumption44–46 and the need for 
multiple tests over time to establish persistently elevated ALT levels in patients.44
These findings are supported by previous studies: A recent study found that a testing 
strategy based on the 1946–1964 birth cohort would identify 76% of anti-HCV+ people16; 
other studies have produced similar estimates using the 1945–1964 birth cohort.1,47 
Likewise, our finding that the ALT strategy would identify 50% of anti-HCV cases is 
consistent with previous population-based estimates.64,65 The birth cohort strategy has been 
found to be cost-effective67–69 and adoption of this approach has the potential to lead to the 
diagnosis of substantially more HCV infections compared to the ALT strategy.
There are several limitations to this study. First, NHANES samples include only the U.S. 
civilian, non-institutionalized population; the exclusion of high-prevalence populations (e.g., 
incarcerated and homeless persons) likely underestimates anti-HCV prevalence. Second, the 
sensitivity of the ALT strategy varies with the choice of ULN, which varies by the laboratory 
conducting the test. In this study, it was found that using a ULN of 31 U/L for men and 20 
U/L for women45 can lead to the identification of nearly 76% of anti-HCV+ people. This 
would make the ALT strategy comparable to the birth cohort strategy on the basis of 
sensitivity. However, based on our review of the limitations of risk-based screening and the 
ALT strategy, we believe that an ALT strategy that recommends gender or other 
demographic-specific cut-off levels would be no less difficult to implement than the current 
screening guidelines. Historically, a ULN of 40 U/L has been generally adopted,10,16,36,43,70 
although this may change in the future.41,45,71
Third, elevated ALT level was defined based on a one-time measurement of serum ALT 
activity. It is reasonable to think that if NHANES captured longitudinal data from which 
persistence of ALT elevation could be examined, the sensitivity of the ALT approach in 
identifying anti-HCV+ individuals could be diminished,65 as fewer have PNALT than those 
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with a single elevated ALT, and consequently the advantage of the birth cohort strategy 
could be more pronounced.
Finally, key implementation assumptions were made about both strategies, which may not 
hold in practice and inflate the reported effectiveness of both strategies. The birth cohort 
strategy assumes that all people born during 1945–1965 would be tested. The ALT strategy 
implies that providers would have unrestricted access to patient medical records, that ALT 
levels are regularly evaluated, and all individuals with elevated ALT levels would be tested 
for HCV infection. Results from this study indicate that substantial proportions of anti-HCV
+ adults do not have health insurance coverage. Accordingly, not all adults would have 
access to health care under either strategy. Of those with some access to health services, not 
all would be tested. For example, under the birth cohort strategy, cohort members may refuse 
testing because of perceived absence of historic risk factors or fear of stigma. Similarly, 
under the ALT strategy, ALT levels may not be measured for all patients seeking primary 
care and a substantial proportion of patients with elevated ALT levels may not be tested for 
HCV.9,35
The CDC and the U.S. Preventive Services Task Force recommend a onetime HCV test for 
all people born during 1945–1965 without the need for solicitation of behavioral or clinical 
risk factors.48,72 The current study provides important evidence for the effectiveness of the 
birth cohort strategy in identifying HCV cases that would go unidentified using an ALT-only 
strategy. However, we expect the implementation of the birth cohort screening strategy to 
happen concurrently with the continued use of ALT-based screening, resulting in averting 
more HCV-related illnesses and deaths. The results of this study indicate that combining the 
birth cohort and ALT strategies would identify more than 87% of anti-HCV cases.
The CDC is actively working to support implementation through development of best 
practices for integrating testing into medical settings (e.g., use of electronic health systems) 
and development of quality indicators and performance measures. The CDC has augmented 
testing capacity using Prevention for Public Health Funds and is educating the public about 
HCV and the need for testing while simultaneously providing clinicians training to improve 
testing and care through the Know More Hepatitis campaign (cdc.gov/knowmorehepatitis).
The CDC has also conducted panels with stakeholder groups (providers, public health 
professionals, health plans and payers, laboratories, and federal partners)48 and is 
implementing strategies with these partners. The birth cohort HCV testing recommendation 
has been adopted by the American Medical Association, American College of Physicians, 
American Association for the Study of Liver Disease, and Infectious Diseases Society of 
America.73–75
It is expected that increasing the proportion of people who have knowledge of their HCV 
infection will result in increases in linkage to care and treatment as well as provision of 
prevention services. Among those for whom treatment is contraindicated, prevention 
strategies to avoid disease transmission (e.g., risk reduction interventions for persons who 
inject drugs) and attenuate progression of liver disease (e.g., reducing use of alcohol) are 
available. In conclusion, the CDC recommends that healthcare providers prioritize the 
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implementation of the birth cohort testing strategy to achieve the public health goals of 
reducing morbidity and mortality associated with HCV infection.48
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Figure 1. 
Participant flow and response rates, adults aged 20–70 years, NHANES 1999–2008
aNHANES publishes screen samples for adults aged 20–29, 30–39, 40–49, 50–59, 60–69, 
70–79, and ≥80 years The screen sample for adults aged 70 years is not published by the 
single-year age group. Thus, we estimated the screen sample for persons aged 20–70 years 
based on the interview response rate for persons aged 20–69 years (76.4%; cdc.gov/nchs/
nhanes/response_rates_cps.htm).
bThe denominator used to calculate the response rate was estimated as described above.
HCV, hepatitis C virus; NHANES, National Health and Nutrition Examination Survey
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Table 1
Characteristics of adults aged 20–70 years, National Health and Nutrition Examination Survey 1999–2008
Characteristic
All participants Anti-HCV-positive
Unweighted, n Weighted, % (95% CI) Unweighted, n Weighted, % (95% CI)
Overall 19,055 429
Age (years; M [SE]) 19,055 42.7 (0.2) 429 45.7 (0.5)
Born from 1945 to 1965
 No 11,332 53.2 (52.1, 54.2) 121 23.4 (18.8, 28.9)
 Yes 7,723 46.8 (45.8, 47.9) 308 76.6 (71.1, 81.2)
Serum alanine aminotransferase level (U/L)
 <40 16,635 88.2 (87.6, 88.8) 204 50.0 (43.8, 56.2)
 ≥40 2,264 11.8 (11.2, 12.4) 217 50.0 (43.8, 56.2)
Gender
 Female 9,981 51.0 (50.4, 51.6) 153 37.2 (31.0, 43.7)
 Male 9,074 49.0 (48.4, 49.6) 276 62.8 (56.3, 69.0)
Race/ethnicity
 Non-Hispanic white 8,726 70.0 (67.2, 72.7) 178 66.5 (60.9, 71.7)
 Non-Hispanic black 3,961 10.9 (9.4, 12.6) 147 20.0 (16.2, 24.5)
 Mexican American 4,391 8.3 (7.1, 9.7) 73 6.5 (4.4, 9.5)
 Other 1,977 10.8 (9.2, 12.6) 31 7.0 (4.3, 11.1)
Family income to poverty threshold
 >2 times 9,920 67.6 (65.7, 69.4) 138 41.6 (36.1, 47.4)
 1–2 times 4,334 19.1 (17.9, 20.4) 128 28.8 (23.6, 34.6)
 Below 3,403 13.3 (12.3, 14.3) 137 29.6 (24.4, 35.3)
Health insurance coverage
 Yes 14,179 79.8 (78.5, 81.0) 285 65.3 (59.5, 70.8)
 No 4,746 20.2 (19.0, 21.5) 136 34.7 (29.2, 40.5)
Served in the U.S. armed forces
 No 16,977 88.3 (87.6, 89.1) 350 83.2 (77.6, 87.6)
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Characteristic
All participants Anti-HCV-positive
Unweighted, n Weighted, % (95% CI) Unweighted, n Weighted, % (95% CI)
 Yes 2,074 11.7 (10.9, 12.4) 78 16.8 (12.4, 22.4)
Average number of alcoholic drinks per day, last year
 0–1 6,168 32.2 (31.0, 33.4) 57 12.7 (9.0, 17.6)
 ≥2 8,305 46.7 (45.3, 48.1) 223 57.6 (51.4, 63.5)
 Unknown 4,582 21.1 (20.0, 22.3 ) 149 29.7 (25.0, 34.8)
Lifetime drug use (20–59a years, n=15,138)
 Never 10,963 71.8 (70.3, 73.2) 84 23.2 (18.0, 29.4)
 Non-IDU 2,469 17.8 (16.7, 19.0) 93 22.9 (18.8, 27.5)
 IDU 297 2.1 (1.8, 2.5) 149 43.4 (37.6, 49.5)
 Unknown 1,409 8.3 (7.6, 9.1) 43 10.4 (7.5, 14.4)
Blood transfusion prior to 1992
 No 17,576 93.7 (93.2, 94.1) 354 84.8 (79.9, 88.7)
 Yes 1,222 6.3 (5.9, 6.8) 63 15.2 (11.3, 20.1)
aNHANES data collection on certain risk factors are limited to participants aged 20–59 years at time of survey.
Anti-HCV, HCV antibody; HCV, hepatitis C virus; IDU, injection drug use; NHANES, National Health and Nutrition Examination Survey
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Table 2
Prevalence of hepatitis C virus antibody by participant characteristics, adults aged 20–70 years, National 
Health and Nutrition Examination Survey 1999–2008
Characteristic Participants, n Weighted anti-HCV prevalence, % (95% CI) p-value
Overall 19,055 2.0 (1.8, 2.3)
Born from 1945 to 1965
 No 11,332 0.9 (0.7, 1.1) ref
 Yes 7,723 3.2 (2.8, 3.8) <0.001
Serum alanine aminotransferase level (U/L)
 <40 16,635 1.1 (0.9, 1.3) ref
 ≥40 2,264 8.4 (7.0, 9.9) <0.001
Gender
 Female 9,981 1.4 (1.2, 1.8) ref
 Male 9,074 2.5 (2.2, 3.0) <0.001
Race/ethnicity
 Non-Hispanic white 8,726 1.9 (1.6, 2.2) ref
 Non-Hispanic black 3,961 3.6 (3.1, 4.3) <0.001
 Mexican American 4,391 1.6 (1.1, 2.2) 0.26
 Other 1,977 1.3 (0.8, 2.1) 0.10
Family income to poverty threshold
 >2 times 9,920 1.2 (1.0, 1.5) ref
 1–2 times 4,334 3.0 (2.4, 3.7) <0.001
 Below 3,403 4.4 (3.7, 5.3) <0.001
Health insurance coverage
 Yes 14,179 1.6 (1.4, 1.9) ref
 No 4,746 3.4 (2.7, 4.1) <0.001
Served in the U.S. armed forces
 No 16,977 1.9 (1.6, 2.2) ref
 Yes 2,074 2.9 (2.1, 3.9) <0.05
Average number of alcoholic drinks per day, last year
 0–1 6,168 0.8 (0.5, 1.1) ref
 ≥2 8,305 2.5 (2.1, 2.9) <0.001
 Unknown 4,582 2.8 (2.3, 3.4)) <0.001
Lifetime drug use (20–59a years, n=15,138)
 Never 10,963 0.7 (0.5, 0.9) ref
 Non-IDU 2,469 2.8 (2.2, 3.5) <0.001
 IDU 297 44.5 (37.9, 51.3) <0.001
 Unknown 1,409 2.7 (1.9, 3.8) <0.001
Blood transfusion prior to 1992
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Characteristic Participants, n Weighted anti-HCV prevalence, % (95% CI) p-value
 No 17,576 1.8 (1.5, 2.1) ref
 Yes 1,222 4.7 (3.4, 6.4) <0.001
Note: Boldface indicates statistical significance.
aNHANES data collection on certain risk factors are limited to participants aged 20–59 years at time of survey.
Anti-HCV, HCV antibody; HCV, hepatitis C virus; IDU, injection drug use; NHANES, National Health and Nutrition Examination Survey
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Table 3
Hepatitis C virus testing strategy, 1945–1965 birth cohort versus elevated alanine aminotransferase levels
Testing strategy
Elevated ALT 1945–1965 birth cohort
Anti-HCV+ adults aged 20–70 years, n 3.6 3.6
Adults testeda, n 21.5 85.5
Anti-HCV-positive persons identified by strategy, n 1.8 2.8
Current HCV infections identified by strategyb, n 1.4–1.5 2.1–2.4
Sensitivityc, % 50 76.6
Note: Values are in millions unless otherwise noted.
a
Based on 10-year average population from 1999–2008 NHANES and may differ from actual total eligible for testing
b
Based on 75%–85% of weighted frequency of identified anti-HCV-positive persons
cSensitivity was defined as the percentage of total anti-HCV-positive cases identified by the testing strategy.
ALT, alanine aminotransferase; anti-HCV, HCV antibody; HCV, hepatitis C virus; NHANES, National Health and Nutrition Examination Survey
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